Full Text
PDB4- COST-EFFECTIVENESS AND CARDIOVASCULAR RISK-AN ANALYSIS OF ROSIGLITAZONE COMPARED WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

Abstract

Authors

PI Oh LG Shane

Back to Volume 4, Issue 2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×